Moderna, Vaxcyte, and Amgen Lead Biotech Stocks to Watch

Moderna (MRNA), Vaxcyte (PCVX), and Amgen (AMGN) are three biotech stocks currently capturing investor attention, according to MarketBeat's stock screener tool. These companies are among the most actively traded biotech stocks in recent days, reflecting heightened interest in the sector. Biotech stocks, while offering significant growth potential, come with elevated risks due to factors like clinical trial outcomes, regulatory decisions, and high research costs.

Moderna, known for its messenger RNA (mRNA) therapeutics and vaccines, has a diverse portfolio targeting infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular diseases. Its respiratory vaccines include those for COVID-19, influenza, and respiratory syncytial virus, among others. Despite a recent 177% surge, Moderna currently holds a Hold rating among analysts, with top-rated analysts suggesting other stocks may be better buys.

Vaxcyte is a clinical-stage biotechnology company focused on developing novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate, VAX-24, is an investigational pneumococcal conjugate vaccine aimed at preventing invasive pneumococcal disease. The company also has other vaccine candidates in development, such as VAX-31 and VAX-A1, addressing emerging strains and antibiotic resistance.

Amgen, a well-established biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. Its principal products include treatments for various conditions such as plaque psoriasis, rheumatoid arthritis, osteoporosis, and multiple myeloma. Amgen's diverse portfolio underscores its role as a key player in the biotech industry.